Deborah M Money1, Erin Moses2, Sandra Blitz3, Shannon M Vandriel4, Nancy Lipsky2, Sharon L Walmsley5, Mona Loutfy6, Sylvie Trottier7, Fiona Smaill8, Mark H Yudin9, Marina Klein10, Marianne Harris11, Jeffrey Cohen12, Wendy Wobeser13, Ari Bitnun14, Normand Lapointe15, Lindy Samson16, Jason Brophy16, Christos Karatzios17, Gina Ogilvie18, François Coutlée19, Janet Raboud20. 1. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada; Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN), Vancouver, BC, Canada. Electronic address: dmoney@cw.bc.ca. 2. Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada. 3. Toronto General Research Institute, University Health Network, Toronto, ON, Canada. 4. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada. 5. Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN), Vancouver, BC, Canada; Toronto General Research Institute, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. 6. Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN), Vancouver, BC, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Department of Medicine, Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 7. Département Microbiologie-infectiologie et immunologie, Université Laval, QC, Canada. 8. Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. 9. Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. 10. Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN), Vancouver, BC, Canada; Canada Chronic Viral Illness Service, Montreal Chest Institute, McGill University Health Centre, Montreal, QC, Canada. 11. AIDS Research Program, St. Paul's Hospital, Vancouver, BC, Canada; Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 12. HIV Care Program, Windsor Regional Hospital, Windsor, ON, Canada. 13. Department of Medicine at Queen's University, Kingston, ON, Canada. 14. Department of Pediatrics, University of Toronto, Toronto, ON, Canada; The Hospital for Sick Children, Toronto, ON, Canada. 15. Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada; Centre maternel et infantile sur le SIDA, CHU Sainte-Justine, Montreal, QC, Canada. 16. Department Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada. 17. Department of Paediatrics, Centre hospitalier universitaire Sainte-Justine, Université de Montréal, Montreal, QC, Canada; Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada. 18. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada; Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; BC Centre for Disease Control, Vancouver, BC, Canada. 19. Departement de Microbiologie et Infectiologie, Hôpital Notre-Dame Du Centre De Recherche Du Centre Hospitalier De L'Uuniversité De Montréal, Montreal, QC, Canada. 20. Toronto General Research Institute, University Health Network, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Abstract
OBJECTIVE: To evaluate the immunogenicity and safety of the quadrivalent HPV (qHPV) vaccine in HIV-positive women over 24months. DESIGN: Between November 2008 and December 2012, 372 women aged 15 and older were enrolled from 14 Canadian HIV outpatient clinics in an open label cohort study. The qHPV vaccine (0.5mL) was administered intramuscularly at months 0, 2 and 6. The primary study endpoint was seroconversion to any of the HPV types targeted by the qHPV vaccine. Antibody levels were measured at 0, 2, 7, 12, 18, and 24months. Adverse events were recorded throughout. RESULTS: Of 372 participants enrolled, 310 (83%) received at least one dose of the qHPV vaccine and 277 (74%) received all three doses. Ninety-five percent (293/308) were seronegative for at least one vaccine type at baseline. The median age was 38years (IQR 32-45, range 15-66), 36% were white, 44% black and 13% were of Indigenous origin. Seventy-two percent of participants had a suppressed HIV viral load (VL<40c/ml) at baseline, with a median CD4 count of 510cells/mm(3) (376-695). Month 7 HPV type-specific seroconversion rates were 99.0%, 98.7%, 98.1% and 93.6% for HPV types 6, 11, 16 and 18 respectively in the per-protocol population. Participants with suppressed HIV VL at first vaccine had a 1.74-3.05fold higher peak antibody response compared to those without (p from 0.006 to <0.0001). CONCLUSIONS: This study is the first to examine the qHPV vaccine in HIV-positive women out to 24months and the first to include HIV-positive women through to age 66. The qHPV vaccine was well tolerated, and highly immunogenic. As women with suppressed viral load had higher antibody responses, planning HPV vaccination to occur when persons are virologically suppressed would be optimal for maximizing immune response. Findings provide strong evidence that older HIV-positive women can still benefit from HPV vaccination. CLINICAL TRIAL REGISTRATION: http://www.isrctn.com/ISRCTN33674451.
OBJECTIVE: To evaluate the immunogenicity and safety of the quadrivalent HPV (qHPV) vaccine in HIV-positive women over 24months. DESIGN: Between November 2008 and December 2012, 372 women aged 15 and older were enrolled from 14 Canadian HIV outpatient clinics in an open label cohort study. The qHPV vaccine (0.5mL) was administered intramuscularly at months 0, 2 and 6. The primary study endpoint was seroconversion to any of the HPV types targeted by the qHPV vaccine. Antibody levels were measured at 0, 2, 7, 12, 18, and 24months. Adverse events were recorded throughout. RESULTS: Of 372 participants enrolled, 310 (83%) received at least one dose of the qHPV vaccine and 277 (74%) received all three doses. Ninety-five percent (293/308) were seronegative for at least one vaccine type at baseline. The median age was 38years (IQR 32-45, range 15-66), 36% were white, 44% black and 13% were of Indigenous origin. Seventy-two percent of participants had a suppressed HIV viral load (VL<40c/ml) at baseline, with a median CD4 count of 510cells/mm(3) (376-695). Month 7 HPV type-specific seroconversion rates were 99.0%, 98.7%, 98.1% and 93.6% for HPV types 6, 11, 16 and 18 respectively in the per-protocol population. Participants with suppressed HIV VL at first vaccine had a 1.74-3.05fold higher peak antibody response compared to those without (p from 0.006 to <0.0001). CONCLUSIONS: This study is the first to examine the qHPV vaccine in HIV-positive women out to 24months and the first to include HIV-positive women through to age 66. The qHPV vaccine was well tolerated, and highly immunogenic. As women with suppressed viral load had higher antibody responses, planning HPV vaccination to occur when persons are virologically suppressed would be optimal for maximizing immune response. Findings provide strong evidence that older HIV-positive women can still benefit from HPV vaccination. CLINICAL TRIAL REGISTRATION: http://www.isrctn.com/ISRCTN33674451.
Authors: Maryse Larouche; Arianne Y K Albert; Nancy Lipsky; Sharon Walmsley; Mona Loutfy; Fiona Smaill; Sylvie Trottier; Ari Bitnun; Mark H Yudin; Geoffrey W Cundiff; Deborah M Money Journal: Int Urogynecol J Date: 2020-05-22 Impact factor: 2.894
Authors: Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke Journal: Cochrane Database Syst Rev Date: 2019-11-22
Authors: François Coutlée; Alexandra de Pokomandy; Ann N Burchell; Mariam El-Zein; Marie-Hélène Mayrand; Sophie Rodrigues-Coutlée; Deborah Money; Émilie Comète; Elisabeth McClymont; Danielle Rouleau; Eduardo L Franco Journal: J Med Virol Date: 2022-01-28 Impact factor: 20.693
Authors: S M Garland; J M L Brotherton; A B Moscicki; A M Kaufmann; M Stanley; N Bhatla; R Sankaranarayanan; S de Sanjosé; J M Palefsky Journal: Papillomavirus Res Date: 2017-06-03